Alpha-1 Antitrypsin Deficiency Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Alpha 1 Antitrypsin Deficiency Pipeline Report to explore emerging therapies, key Alpha 1 Antitrypsin Deficiency Companies, and future Alpha 1 Antitrypsin Deficiency treatment landscapes @ Alpha 1 Antitrypsin Deficiency Pipeline Outlook Report
Key Takeaways from the Alpha 1 Antitrypsin Deficiency Pipeline Report
In February 2025:- Grifols Therapeutics Inc.:- The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in participants with Alpha1-Antitrypsin Deficiency (AATD).
In January 2025:- Takeda:- The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually endstage liver disease.
In January 2025:- Korro Bio Inc.:- The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).
In January 2025:- Arrowhead Pharmaceuticals: - The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
In January 2025:- Kamada Ltd:- The goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD).
DelveInsight's Alpha 1 Antitrypsin Deficiency pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Alpha 1 Antitrypsin Deficiency treatment.
The leading Alpha 1 Antitrypsin Deficiency Companies such as Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd and others.
Promising Alpha-1 Antitrypsin Deficiency Pipeline Therapies such as Fazirsiran Injection, Aerosolized, Recombinant Alpha 1-Antitrypsin, INBRX-101/rhAAT-Fc, ADVM-043, and others.
Discover how the Alpha 1 Antitrypsin Deficiency treatment paradigm is evolving. Access DelveInsight's in-depth Alpha 1 Antitrypsin Deficiency Pipeline Analysis for a closer look at promising breakthroughs @ Alpha 1 Antitrypsin Deficiency Clinical Trials and Studies
Alpha 1 Antitrypsin Deficiency Emerging Drugs Profile
ARO AAT: Arrowhead Pharmaceuticals
ARO AAT is a second generation, N-Acetylgalactosamine (GalNAc) based, subcutaneously administered RNA interference based therapeutic. ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. In June 2019, the US FDA has granted Fast Track designation to ARO-AAT. ARO-AAT is in Phase III clinical studies for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD).
ALN-AAT02: Alnylam Pharmaceuticals
ALN AAT02 is a subcutaneously administered RNAi therapeutic that targets alpha-1 antitrypsin (AAT). ALN-AAT02 is based on the Alnylam's enhanced stabilization chemistry plus (ESC+)-GalNAc-conjugate technology, which enables subsequent subcutaneous dosing with increased selectivity and a wide therapeutic index. The drug is currently in Phase I/II clinical development for the treatment of ZZ Type AAT Deficiency Liver Disease.
The Alpha 1 Antitrypsin Deficiency pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Alpha 1 Antitrypsin Deficiency with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha 1 Antitrypsin Deficiency Treatment.
Alpha 1 Antitrypsin Deficiency Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Alpha 1 Antitrypsin Deficiency Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha 1 Antitrypsin Deficiency market.
Get a detailed analysis of the latest innovations in the Alpha 1 Antitrypsin Deficiency pipeline. Explore DelveInsight's expert-driven report today! @ Alpha 1 Antitrypsin Deficiency Unmet Needs
Alpha 1 Antitrypsin Deficiency Companies
Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd and others.
Alpha 1 Antitrypsin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Alpha 1 Antitrypsin Deficiency Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming Alpha 1 Antitrypsin Deficiency Therapies and key Alpha 1 Antitrypsin Deficiency Developments @ Alpha 1 Antitrypsin Deficiency Market Drivers and Barriers, and Future Perspectives
Scope of the Alpha 1 Antitrypsin Deficiency Pipeline Report
Coverage- Global
Alpha 1 Antitrypsin Deficiency Companies- Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd and others.
Alpha-1 Antitrypsin Deficiency Pipeline Therapies - Fazirsiran Injection, Aerosolized, Recombinant Alpha 1-Antitrypsin, INBRX-101/rhAAT-Fc, ADVM-043, and others.
Alpha 1 Antitrypsin Deficiency Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Alpha 1 Antitrypsin Deficiency Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Alpha 1 Antitrypsin Deficiency drug development? Find out in DelveInsight's exclusive Alpha 1 Antitrypsin Deficiency Pipeline Report—access it now! @ Alpha 1 Antitrypsin Deficiency Emerging Drugs and Major Companies
Table of Content
Introduction
Alpha-1 Antitrypsin Deficiency Executive Summary
Alpha-1 Antitrypsin Deficiency: Overview
Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics
Alpha-1 Antitrypsin Deficiency Pipeline Therapeutic Assessment
Alpha-1 Antitrypsin Deficiency– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
ARO AAT: Arrowhead Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
ALN-AAT02: Alnylam Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Alpha-1 Antitrypsin Deficiency Key Companies
Alpha-1 Antitrypsin Deficiency Key Products
Alpha-1 Antitrypsin Deficiency- Unmet Needs
Alpha-1 Antitrypsin Deficiency- Market Drivers and Barriers
Alpha-1 Antitrypsin Deficiency- Future Perspectives and Conclusion
Alpha-1 Antitrypsin Deficiency Analyst Views
Alpha-1 Antitrypsin Deficiency Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/surgical-lasers-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
9 hours ago
- Globe and Mail
Oncocytoma Market Poised for Growth Through 2032, Fueled by AI Diagnostics and Minimally Invasive Surgery
The Oncocytoma market is experiencing notable growth, with the 7MM projected to achieve a decent CAGR, according to DelveInsight's latest analysis. This growth reflects advancements in molecular diagnostics and minimally invasive surgical technologies that are reshaping treatment paradigms for this rare renal and salivary gland tumor. DelveInsight's report, ' Oncocytoma - Market Insight, Epidemiology And Market Forecast - 2032 ', provides a comprehensive assessment of oncocytoma market dynamics, disease epidemiology, and treatment advancements across the 7MM. The report forecasts that the oncocytoma market size in 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase notably over the coming years. This growth is primarily driven by the increased adoption of non-invasive treatment options and advancements in early detection technologies. The United States represents the largest share of the oncocytoma market. The EU4 countries and the United Kingdom collectively make up the second-largest market share. Download the oncocytoma market report to understand which factors are driving the oncocytoma therapeutic market @ Oncocytoma Market Trends. The epidemiological data presented in the report indicate key trends in incidence, demographics, and the oncocytoma patient pool. The data reveal a steadily expanding oncocytoma patient pool across the 7MM, with the median age at diagnosis for renal oncocytoma typically ranging from 62 to 68 years. Additionally, it has also been indicated that oncocytomas predominantly affect males across the studied regions. The report also explores the current and evolving Oncocytoma treatment landscape. As of now, there are no FDA-approved drugs specifically targeting oncocytoma. Instead, oncocytomas are typically managed through surgical excision (such as partial or radical nephrectomy) or minimally invasive techniques like cryoablation or radiofrequency ablation when necessary. While surgical intervention remains the cornerstone of current management, there is an accelerated innovation in diagnostic accuracy and the differentiation of these tumors from malignant renal counterparts. Recently, AI-driven diagnostic tools have been integrated into clinical practice, showing promising results in the diagnosis and preoperative planning for oncocytoma. One study revealed that an AI system achieved over 90% accuracy in distinguishing clear cell renal cell carcinoma (RCC) from oncocytoma using MRI scans. Additionally, a comparative analysis indicated that the AI model outperformed radiologists in distinguishing benign tumors, such as oncocytoma and angiomyolipoma, from RCC subtypes. This highlights the potential of AI to reduce diagnostic ambiguity within the oncocytoma treatment landscape. Discover evolving trends in the oncocytoma treatment landscape @ Oncocytoma Therapeutics Market. Looking ahead, the oncocytoma market is set for significant growth, driven by advancements in diagnostic technologies and surgical techniques. Despite challenges posed by the benign nature of these tumors, which can lead to misdiagnosis and potential overtreatment, the field is witnessing a paradigm shift. The integration of artificial intelligence in imaging and the development of molecular diagnostic tools are enhancing the accuracy of preoperative diagnosis, reshaping patient management strategies As research continues to uncover the molecular intricacies of oncocytomas, the market is expected to expand, offering more personalized treatment options and improved long-term monitoring techniques to address the unmet needs in this landscape. Unlock which oncocytoma drug is expected to capture the largest market share in 7MM by 2032. Visit the Oncocytoma Market Insights. Table of Contents 1. Key Insights 2. Executive Summary of Oncocytoma 3. Oncocytoma Competitive Intelligence Analysis 4. Oncocytoma: Market Overview at a Glance 5. Oncocytoma: Disease Background and Overview 6. Oncocytoma Patient Journey 7. Oncocytoma Epidemiology and Patient Population 8. Oncocytoma Treatment Algorithm, Current Treatment, and Medical Practices 9. Oncocytoma Unmet Needs 10. Key Endpoints of Oncocytoma Treatment 11. Oncocytoma Marketed Products 12. Oncocytoma Emerging Therapies 13. Oncocytoma: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Oncocytoma Access and Reimbursement Overview 17. KOL Views 18. Oncocytoma Market Drivers 19. Oncocytoma Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight Related Reports Oncocytoma Pipeline Insight Oncocytoma Pipeline Insight provides comprehensive insights about the oncocytoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the oncocytoma companies. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Globe and Mail
a day ago
- Globe and Mail
ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, ' Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Insight, 2025 ' report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the ESCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ESCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ ESCLC Pipeline Outlook Report Key Takeaways from the ESCLC Pipeline Report In August 2025, Bristol-Myers Squibb announced a study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer. In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS). In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327. DelveInsight's ESCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for ESCLC treatment. The leading ESCLC Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others. Promising ESCLC Pipeline Therapies such as LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others. Learn how leading ESCLC Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!" @ ESCLC Clinical Trials Assessment ESCLC Emerging Drugs Profile Serplulimab+Chemo: Shanghai Henlius Biotech Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase III clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase III clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. Currently, the drug is in Phase III stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC). Vobramitamab duocarmazine (MGC018): MacroGenics, Inc. Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3. Currently, the drug is in Phase II stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC). RYZ101: RayzeBio, Inc. RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. RYZ101 is being combined with current standard of care therapy. Currently, the drug is in Phase I stage of its development for the treatment of of Extensive-Stage Small Cell Lung Cancer (ESCLC). The ESCLC Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of ESCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESCLC Treatment. ESCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. ESCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESCLC market. From early-stage research to late-phase ESCLC Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed—download now! @ ESCLC Treatment Drugs ESCLC Companies Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others. Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical ESCLC Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Stay updated with the latest ESCLC Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ ESCLC Market Drivers and Barriers, and Future Perspectives Scope of the ESCLC Pipeline Report Coverage- Global ESCLC Companies- Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others. ESCLC Pipeline Therapies- LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others. ESCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination ESCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Find answers in our latest ESCLC Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ ESCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary Extensive Stage Small Cell Lung Cancer (ESCLC): Overview Pipeline Therapeutics Therapeutic Assessment Extensive-Stage Small Cell Lung Cancer (ESCLC) – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Serplulimab+Chemo: Shanghai Henlius Biotech Mid-Stage Products (Phase II) Vobramitamab duocarmazine (MGC018): MacroGenics, Inc. Early Stage Products (Phase I) RYZ101: RayzeBio, Inc. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Globe and Mail
6 days ago
- Globe and Mail
ER+/ HER2-VE Breast Cancer Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'ER positive, HER2 negative Breast Cancer Pipeline Insight 2025' report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in ER positive, HER2 negative Breast Cancer pipeline landscape. It covers the ER+/ HER2 -ve Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ER+/ HER2 -ve Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive ER+/ HER2 -ve Breast Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report In August 2025, Yale University announced a phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Patients with ER+ breast cancer anatomic stage IIB or III at diagnosis who are at least five years from diagnosis and have completed intended course of adjuvant endocrine therapy and are currently off endocrine therapy will be screened with ctDNA testing. In July 2025, Atossa Therapeutics Inc. announced a study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part. DelveInsight's ER+/ HER2 -ve Breast Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for ER+/ HER2 -ve Breast Cancer treatment. The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. Promising ER+/ HER2 -ve Breast Cancer Therapies such as Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others. Discover how the ER+/ HER2 -ve Breast Cancer treatment paradigm is evolving. Access DelveInsight's in-depth pipeline Analysis for a closer look at promising breakthroughs @ ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies Camizestrant: AstraZeneca Camizestrant, is a next-generation oral selective estrogen receptor degrader (SERD), as a promising treatment for ER-positive, HER2-negative breast cancer. This drug, developed by AstraZeneca, and has shown significant potential in improving progression-free survival (PFS) compared to the standard treatment with fulvestrant, which has been the mainstay therapy for almost two decades. Camizestrant has demonstrated significant efficacy in clinical trials, particularly the SERENA-2 phase II trial. In this study, camizestrant was compared to fulvestrant, a well-established treatment. Patients receiving camizestrant showed improved progression-free survival (PFS) at doses of 75 mg and 150 mg, with median PFS of 7.2 and 9.2 months, respectively, compared to 3.7 months for those on fulvestrant. This trial also highlighted camizestrant's ability to reduce ESR1-mutant circulating tumor DNA, indicating a strong efficacy in combatting endocrine-resistant tumors. Safety profiles from these studies indicate that camizestrant is generally well-tolerated, with manageable side effects such as fatigue, anemia, and mild visual disturbances. The favorable balance between efficacy and safety has supported the advancement of camizestrant into further phase III trials, like SERENA-4 and SERENA-6, which are exploring its use in combination with CDK4/6 inhibitors for broader clinical application. Currently, the drug is in Phase III stage of its development for the treatment of HER2-negative breast cancer. (Z)-endoxifen: Atossa Therapeutics, Inc. (Z)-endoxifen is the most active metabolite of the FDA approved Selective Estrogen Receptor Modulator (SERM), tamoxifen. Studies have demonstrated that the therapeutic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifen. In addition to its potent anti-estrogen effects, (Z)-endoxifen at higher concentrations has been shown to target PKCβ1, a known oncogenic protein. (Z)-endoxifen also appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. Atossa is developing a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach as acidic conditions in the stomach convert a greater proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa's (Z)-endoxifen has been shown to be well tolerated in Phase I studies and in a small Phase II study of women with breast cancer. Currently, the drug is in Phase II stage of its development for the treatment of ER-positive, HER2-negative breast cancer. AC699 is a potent and selective orally bioavailable, chimeric degrader of estrogen receptor (ER) α, and offers a potential new breast cancer treatment option based on a differentiated mechanism of action as compared to fulvestrant and novel SERDs with deeper ERα degradation as demonstrated in preclinical studies. AC699 is currently being evaluated in an ongoing Phase I clinical study as a single agent for the treatment of ER-positive / HER2-negative locally advanced or metastatic breast cancer. The primary objectives are to evaluate the safety and tolerability of AC699. Secondary and exploratory objectives include pharmacokinetics, preliminary efficacy and pharmacodynamic evaluation. The study uses a 3+3 dose-escalation design, with once-daily oral dosing of AC699 at 100, 200, 300, 400, and 600 mg. The ER+/ HER2 -ve Breast Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of ER+/ HER2 -ve Breast Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ER+/ HER2 -ve Breast Cancer Treatment. ER+/ HER2 -ve Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. ER+/ HER2 -ve Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ER+/ HER2 -ve Breast Cancer market. Get a detailed analysis of the latest innovations in the ER+/ HER2 -ve Breast Cancer pipeline. Explore DelveInsight's expert-driven report today! @ ER+/ HER2 -ve Breast Cancer Unmet Needs ER+/ HER2 -ve Breast Cancer Companies AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical ER+/ HER2 -ve Breast Cancer Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming ER+/ HER2 -ve Breast Cancer Therapies and key developments @ ER+/ HER2 -ve Breast Cancer Market Drivers and Barriers, and Future Perspectives Scope of the ER+/ HER2 -ve Breast Cancer Pipeline Report Coverage- Global ER+/ HER2 -ve Breast Cancer Companies- AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. ER+/ HER2 -ve Breast Cancer Therapies- Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others. ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in ER+/ HER2 -ve Breast Cancer drug development? Find out in DelveInsight's exclusive pipeline Report—access it now! @ ER+/ HER2 -ve Breast Cancer Emerging Drugs and Major Companies Table of Content Introduction Executive Summary ER+/ HER2-VE Breast Cancer: Overview Pipeline Therapeutics Therapeutic Assessment ER positive, HER2 negative Breast Cancer– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Camizestrant: AstraZeneca Drug profiles in the detailed report….. Mid Stage Products (Phase II) (Z)-endoxifen: Atossa Therapeutics, Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) AC699: Accutar Biotechnology Inc Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products ER+/ HER2-VE Breast Cancer Key Companies ER+/ HER2-VE Breast Cancer Key Products ER+/ HER2-VE Breast Cancer- Unmet Needs ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion ER+/ HER2-VE Breast Cancer Analyst Views ER+/ HER2-VE Breast Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
